Colorectal Cancer Screening Attitudes and Practices in the General Population: A Risk-adjusted Survey

Size: px
Start display at page:

Download "Colorectal Cancer Screening Attitudes and Practices in the General Population: A Risk-adjusted Survey"

Transcription

1 Colorectal Cancer Screening Attitudes and Practices in the General Population: A Risk-adjusted Survey Walter L. Straus, Edward C. Mansley, Karen F. Gold, Qin Wang, Prabashni Reddy, and Chris L. Pashos Objectives: To characterize self-reported colorectal cancer (CRC) screening behavior, and to identify characteristics of CRC screening practices, stratified by risk. Methods: Using random-digit-dial methodology, we conducted telephone surveys in US adults 50 years of age and older. Respondents provided data on utilization of CRC screening tests; demographic characteristics; and awareness, concerns, attitudes and beliefs about the tests, CRC, and health care. On the basis of available guidelines, three definitions of adequate screening were considered. Results: Among persons reporting having ever had a CRC screening exam, the exam was more likely to have been a fecal occult blood test than a radiologic or endoscopic exam (p <.0001). Subjects at increased CRC risk were more likely to have met the screening criteria (p <.001) compared with average-risk subjects. Receipt of information or advice about cancer screening tests, male gender, and concern about managed care were positively associated with adequate screening. Smoking, low health self-monitoring, and an average risk for CRC reduced the probability of CRC screening. Conclusions: Lack of awareness about screening remains common, regardless of CRC risk. Providing information and advice about cancer screening may be the single most important tool available to improve screening rates. KEY WORDS: cancer prevention, cancer screening, colorectal cancer Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States, accounting for 10 percent of all cancer mortality. Early detection of CRC can dramatically increase an individual s survival rate. Data from the National Cancer Institute show that 90 percent of patients who are diagnosed early will survive beyond 5 years. In contrast, 8 percent of patients J Public Health Management Practice, 2005, 11(3), C 2005 Lippincott Williams & Wilkins, Inc. diagnosed after their disease has reached an advanced state will survive beyond 5 years. 1 Currently, CRC prevention has a larger number of distinct screening modalities than any other cancer. These methods include the fecal occult blood test (FOBT); endoscopic tests, including flexible sigmoidoscopy (SIG) and colonoscopy (COL); and doublecontrast barium enema (DCBE). 2 Furthermore, the arsenal of screening tools is expanding with recent advances in virtual colonoscopy and stool-based DNA assays. 3 Despite the proven value and diversity of screening procedures, screening rates remain low. Recent data from the US Centers for Disease Control and Prevention (CDC) show that only 40.3 percent of US residents more than age 50 have ever received a home-administered FOBT and only 43.8 percent have ever received an SIG or a COL. Furthermore, only 20.6 percent of those aged more than 50 had a home-administered FOBT within the past year and only 33.6 percent had an SIG or a COL within the past 5 years. 4 In contrast, screening for cervical cancer and breast cancer, other cancers for which there is also evidence that screening reduces mortality, approaches percent. 5 The public health community has sought to understand the reasons for these low screening rates. In this This research was sponsored by Merck & Co, Inc. Corresponding author: Walter L. Straus, MD, MPH, Merck Research Laboratories, PO Box 4, BL 1-7, West Point, PA ( walter straus@merck.com). Walter L. Straus, MD, MPH, is Senior Director, Epidemiologic Research, Merck Research Laboratories, West Point, Pa. Edward C. Mansley, PhD, is Health Economist, Outcomes Research & Management, Merck & Co, Inc, West Point, Pa. Karen F. Gold, PhD, was formerly Director of Biostatistics and Outcomes Research, Abt Associates, Health Economic Research & Quality of Life Evaluation Services (HERQuLES), Bethesda, Md. Qin Wang, MA, is Lead Programmer Analyst, Abt Associates, HERQuLES, Bethesda, Md. Prabashni Reddy, PharmD, is Associate Director of Clinical Outcomes Research, Abt Associates, HERQuLES, Lexington, Mass. Chris L. Pashos, PhD, Executive Director and Vice President, Abt Associates, HERQuLES, Lexington, Mass. 244

2 A Risk-adjusted Survey 245 regard, studies involving surveys and focus group interviews have been conducted to uncover facilitators and barriers to CRC screening related to the knowledge, attitudes, and practices of physicians and health care providers, 6 11 as well as those related to the knowledge, attitudes, and behaviors of the general population Recent population surveys, however, have been limited typically to small groups usually restricted to certain geographic, age, and ethnic profiles. Although large, national surveys of colorectal cancer screening have been performed, the effects of only a limited number of health behavior factors on colorectal screening have been assessed. The most commonly used CRC screening guidelines provide different recommendations based on the patient s underlying CRC risk. However, to our knowledge, none of these surveys has compared screening experiences for those at average versus those at elevated risk for CRC. 5,19 The primary objectives of the study presented in this paper are to characterize self-reported CRC screening practice in the United States under different definitions of adequate screening ( screening criteria ), and to better understand the population-reported barriers and facilitators associated with adequate screening. Methods We conducted a national random-digit-dial telephone survey of US households in Responding households with no adults 50 years and older were not surveyed. Trained interviewers conducted this computerassisted telephone survey. An empirically derived sample of 500 patients was targeted for the study. Up to 12 attempts were made to reach individuals during a random cross-section of the day (eg, afternoon and evening) and over the course of a week. From each respondent, we collected information on demographic characteristics, CRC risk factors, and attitudes toward and personal screening experience with FOBT, SIG, COL, and DCBE. The survey consisted of 60 questions and the interview lasted approximately 30 minutes. Subjects reported the year in which they received the screening tests (if screened). We defined the year in which these tests were conducted as the most recent year in which they received the test. Because our survey was conducted in the middle of the year, a half-year extension was added to the criteria screening intervals (eg, 1 1 / 2 years vs 1 year for FOBT). On the basis of the respondents answers to questions about personal and family medical history, we classified them as at average or increased risk for CRC. 20,21 Subjects were classified as being at increased risk if they reported having a personal history of polyps, colitis, Crohn s Disease or CRC, or having a blood relative with CRC. We also collected and assessed self-reported data on the subjects awareness, concerns, attitudes, and beliefs about CRC, CRC tests, health, and the health care system that might represent facilitators of, or barriers to, the screening tests. Categories of variables considered to be potential barriers or facilitators included (1) demographics; (2) health-related concerns (eg, concern about quality of care, concern about the disease); (3) receipt of information about cancer screening; (4) specific CRC cancer screening beliefs (eg, CRC is preventable, early detection improves survival, CRC is a public or personal health threat); (5) healthy and risky behaviors (eg, alcohol intake, smoking); (6) insurance coverage; (7) employment status; and (8) lack of knowledge of or negative feelings toward CRC and cancer screening tests (eg, discomfort, unpleasantness), and access to care. This instrument was adapted from others used in cancer screening research After a review of recommended CRC screening practices, we identified six sets of screening practice criteria that corresponded to existing research or public health based recommendations. Three sets pertained to subjects at average risk and three to those at increased risk. We focused on criteria broadly representative of the range of existing recommendations. Specifically, we selected the following guidelines for CRC screening: Criterion I, relatively lax requirements; Criterion II, intermediate requirements; and Criterion III, relatively stringent requirements. The guidelines on which these criteria are based are summarized in Table 1. Respondents were evaluated as to whether their screening practices were adequate, on the basis of their conformance with these criteria. To evaluate conformance with Criterion I, subjects were classified by their screening practices into one of four categories (A, B, C, and D, shown in Table 2), adapted from previous work. 2 Screening practices B, C, and D, involving combinations of FOBT, SIG, DCBE, or COL, are considered adequate for subjects at average risk (Table 2). The only difference in the screening behavior criteria based on risk level was that the COL requirement involved a COL every 10 years for subjects at average risk rather than every 5 years for those at increased risk. 2,20 21 Criterion II reflects a stricter definition of adequate screening, involving a COL every 10 years for subjects at average risk or an alternative annual FOBT in conjunction with either an SIG or a DCBE every 5 years. As with Criteria I, the behavior requested of individuals at increased risk is comparable except that the COL should have occurred within the past 5 years. 20,21 Criterion III, involving an even stricter definition of adequate screening, was based on the American College of Gastroenterology s (ACG) preferred CRC

3 246 Journal of Public Health Management and Practice TABLE 1 Summary of CRC screening guidelines used to develop Criteria I, II, and III American Gastroenterological Association, 1997 (endorsed by multiple organizations) 2 American College of Gastroenterology, ,21 Average risk ( 50 years and no other risk factors for CRC) FOBT Annually SIG Every 5 years SIG + FOBT Every 5 years + annually Every 5 years + annually (alternative strategy) DCBE Every 5 10 years Every 5 years + annual FOBT (alternative strategy) COL Every 10 years Every 10 years Increased risk Close relative with CRC or adenomatous polyp As for average risk but begin screening at COL every 3 10 years beginning at age 40 or 10 years 40 years younger than age of youngest affected relative Family history of adenomatous polyposis SIG annually beginning at puberty SIG every 1 2 years beginning at years Family history of hereditary nonpolyposis CRC COL every 1 2 years age years and COL every 2 years beginning at age 20 25; annually after age 40 annually after age 40 History of adenomatous polyps COL every 3 years COL every 3 5 years COL = colonoscopy; CRC = colorectal cancer; DCBE = double-contrast barium enema; FOBT = fecal occult blood test; SIG = flexible sigmoidoscopy. screening strategy. It includes a COL every 10 years for subjects at average risk and every 5 years for subjects at increased risk. This criterion for adequate screening behavior does not allow the alternative use of tests permitted in Criterion II. 20,21 Analyses were conducted using SAS version Descriptive statistics and simple tabular counts were performed to describe the sample, classify subjects, evaluate different screening criteria, compare screening behavior classification systems, and compare responses of subjects at average risk with those at increased risk on key variables. Chi-square and t tests were implemented to assess statistical significance. Three logistic regressions were constructed to assess the association between adequate screening behavior (as defined above) and the potential barriers and facilitating factors. Within each of the three sets of criteria, adherence to CRC screening was based on CRC risk (ie, average risk and high risk). 20,21 The data contained very few missing values. Missing values were imputed using mean or median values. Twenty-two subjects could not be classified as being at either average risk or increased risk because of missing data and were included in the average risk group. No imputation was done for screening behavior. Small differences in sample sizes presented in descriptive tables and logistic regressions are attributable to the exclusion of subjects not reporting relevant information. Results Of 4,546 households contacted, 1,897 refused to participate in the 30-minute survey. We then excluded 2,147 TABLE 2 Criteria classification for screening behavior of subjects at average risk Is the screening Criteria behavior adequate? Criterion I, includes FOBT only, FOBT plus other test, and non-fobt only categories A Not B, C, or D B FOBT in the past 1 1 / 2 years, but neither an SIG or a DCBE in the past 5 1 / 2 years nor a COL in the past 10 1 / 2 years C NoFOBT in the past 1 1 / 2 years, but either an SIG or a DCBE in the past 5 1 / 2 years or a COL in the past 10 1 / 2 years D FOBT in the past 1 1 / 2 years, and an SIG or a DCBE in the past 5 1 / 2 years or a COL in the past 10 1 / 2 years Criterion II, includes colonoscopy or FOBT plus other test A Not BorC B COL in the past 10 1 / 2 years C FOBT in the past 1 1 / 2 years AND either an SIG or a DCBE in the past 5 1 / 2 years Criterion III, includes colonoscopy only A Not B B COL in the past 10 1 / 2 years COL = colonoscopy; CRC = colorectal cancer; DCBE = double-contrast barium enema; FOBT = fecal occult blood test; SIG = flexible sigmoidoscopy. Note: Colonoscopy interval for subjects at increased risk was 5 1 / 2 years. No No No

4 A Risk-adjusted Survey 247 TABLE 3 Demographic characteristics of sample by risk category Average Increased Overall, risk, n = 306 risk, n = 176 N = 482 (63.5%) (36.5%) (100%) Age (59.8%) 83 (47.2%) 266 (55.2%) (29.7%) 66 (37.5%) 157 (32.6%) (10.5%) 27 (15.3%) 59 (12.2%) Primary ethnicity African American 25 (8.2%) 15 (8.5%) 40 (8.3%) Hispanic or Latino 10 (3.3%) 5 (2.8%) 15 (3.1%) White 251 (82.0%) 146 (83.0%) 397 (82.4%) American Native/Alaskan 13 (4.3%) 5 (2.8%) 18 (3.7%) Asian/Pacific Islander 2 (0.7%) 2 (1.1%) 4 (0.8%) Other 5 (1.6%) 3 (1.7%) 8 (1.7%) Gender Male 90 (29.4%) 46 (26.1%) 136 (28.2%) Female 216 (70.6%) 130 (73.9%) 346 (71.8%) p =.024 vs average risk. (47.2%) as there was no resident 50 years or older. Of the households contacted with an individual 50 years or older, 21 percent elected to participate in the survey (N = 502), of whom 482 were 51 years or older. Subjects 50 years old and those not reporting age were excluded because conformance with age-specific screening recommendations could not be assessed with certainty for those individuals. Therefore, responses of the 482 participants who were 51 years of age or older were analyzed. Overall, 36.5 percent (n = 176) of the subjects fulfilled one or more of the criteria that identified them as being at increased risk for CRC. The most common risk factor, personal history of polyps, was present in 21.6 percent of the overall sample and in 59.1 percent of subjects at increased risk. Nearly half (49.4%) of the population at increased risk reported having a blood relative with CRC, while 11.9 percent of them reported history of colitis or Crohn s disease, and 5.1 percent of them reported personal history of CRC. Demographic characteristics, stratified by CRC risk category, are shown in Table 3. Similar distributions for ethnicity and gender are present across the two risk groups. Compared with subjects at average risk, significantly fewer of those at increased risk are in the youngest age group (p =.024). The proportion of men is not significantly different between the two risk groups (p = 0.44). Of the 502 patients who completed the survey, 20 percent were from the Northeast, 20 percent from the West, 35 percent from the South, and 25 percent were from the Midwest (US 2000 Census data: 19% Northeast, 22% West, 36% South, and 23% Midwest). For both risk groups, the FOBT was the test most frequently received, regardless of CRC risk (p <.0001) TABLE 4 Rates of ever received screening by risk category and screening test Average-risk Increased-risk Colorectal cancer subjects subjects screening test (n = 306) (n = 176) p-value Fecal occult blood test 67.1% 80.7%.003 Flexible sigmoidoscopy 43.0% 69.2%.0001 Colonoscopy 22.5% 73.6%.0001 Double-contrast barium 28.6% 58.6%.0001 enema p <.0001 fecal occult blood test vs other colorectal cancer screening tests. (Table 4). Persons at increased CRC risk were significantly more likely than those at average risk to have ever had each of the four types of screening test. For each of the three screening categories, respondents at increased risk were more likely to have received adequate screening (p <.001) than those at average risk for CRC (Table 5). Moreover, the data also suggest that the screening strategy usually recommended for individuals at increased risk (a COL every 5 years) was not followed by a large percentage of those individuals, as 43.7 percent reported not having a colonoscopy within the past 5 1 / 2 years. After adjustment for covariates, six variables were found to be significantly associated with adequate screening (p <.05) in at least one of the three regressions; five variables were significant in two to three of the three regressions, suggesting robustness of results to variations in the definition of adequate screening (Table 6). Persons who were less concerned about their health (as reflected by low health self-monitoring), who smoked, or who were at average risk for CRC were less likely to have satisfied CRC screening criteria. Conversely, male respondents, those who expressed concerns about managed care, or who had ever received information/advice about cancer screening were more likely to have satisfied the screening criteria. Discussion To our knowledge, this is the first study to assess adherence to CRC screening using different sets of screening TABLE 5 Adequate screening behavior by risk level and screening criteria Screening Average-risk Increased-risk criteria subjects (n = 306) subjects (n = 176) p-value Criteria I 48.7% 77.8%.001 Criteria II 23.5% 64.2%.001 Criteria III 15.7% 56.3%.001

5 248 Journal of Public Health Management and Practice TABLE 6 Association of personal factors with adequate screening behavior for subjects at pooled risk (multivariate logistic regressions) N (%) of subjects conforming with criteria for adequate screening Criterion I Criterion II Criterion III 283 (60%) 183 (39%) 145 (31%) Demographics Male 1.90 (1.11, 3.27) 1.36 (0.79, 2.33) 1.04 (0.59, 1.84) African American/Hispanic 0.69 (0.32, 1.51) 0.98 (0.43, 2.26) 1.02 (0.43, 2.40) Age 1.01 (0.98, 1.05) 1.00 (0.97, 1.04) 1.01 (0.97, 1.04) Health concerns Concern about quality of care 0.96 (0.78, 1.18) 1.03 (0.83, 1.26) 0.96 (0.77, 1.20) Concern about cost of medication 1.18 (0.94, 1.49) 1.14 (0.91, 1.42) 0.95 (0.74, 1.21) Concern about managed care 1.09 (0.91, 1.30) 1.32 (1.10, 1.59) 1.21 (1.01, 1.47) Low health self-monitoring 0.80 (0.70, 0.92) 0.84 (0.72, 0.98) 0.93 (0.80, 1.08) Disease concern 0.95 (0.90, 1.01) 0.95 (0.89, 1.01) 0.96 (0.90, 1.02) Information Ever received about cancer screening tests 2.10 (1.33, 3.31) 2.40 (1.49, 3.88) 1.61 (0.98, 2.65) Cancer screening beliefs CRC preventable via screening 0.98 (0.77, 1.25) 0.88 (0.68, 1.14) 0.85 (0.65, 1.12) Early detection improves CRC survival 0.90 (0.56, 1.45) 1.04 (0.62, 1.74) 1.14 (0.68, 1.92) CRC serious public health threat 0.99 (0.85, 1.16) 1.00 (0.86, 1.18) 1.10 (0.94, 1.30) CRC serious personal threat 0.88 (0.74, 1.04) 0.92 (0.76, 1.11) 0.95 (0.79, 1.15) Health behaviors Smokes 0.48 (0.26, 0.88) 0.60 (0.31, 1.18) 0.47 (0.22, 0.99) Moderate alcohol intake (reference = no alcohol) 1.20 (0.69, 2.07) 1.24 (0.72, 2.14) 0.88 (0.50, 1.56) Heavy alcohol intake (reference = no alcohol) 0.67 (0.37, 1.22) 0.85 (0.45, 1.58) 0.67 (0.35, 1.30) Insurance status Medicare/Veterans Affairs 0.97 (0.52, 1.81) 1.38 (0.73, 2.62) 1.25 (0.65, 2.41) Medicaid 0.80 (0.27, 2.33) 0.60 (0.18, 1.98) 0.54 (0.16, 1.81) Managed care/private 0.82 (0.42, 1.61) 0.88 (0.43, 1.80) 0.84 (0.40, 1.75) Unknown 0.38 (0.10, 1.46) 0.46 (0.11, 2.04) 0.61 (0.14, 2.59) Employment status (reference = full-time) Part time 1.25 (0.55, 2.82) 1.71 (0.75, 3.93) 1.24 (0.51, 3.03) Homemaker 0.75 (0.33, 1.72) 1.32 (0.55, 3.15) 1.75 (0.72, 4.28) Retired 1.26 (0.63, 2.50) 1.02 (0.50, 2.10) 1.18 (0.55, 2.53) Other employment categories 0.57 (0.25, 1.26) 0.86 (0.37, 2.01) 1.54 (0.64, 3.71) Dimensions of knowledge, negative feelings, and access SIG, COL, DCBE Knowledge 0.94 (0.86, 1.03) 0.97 (0.88, 1.06) 0.97 (0.88, 1.07) Fear, discomfort or bothered 1.00 (0.94, 1.06) 1.04 (0.98, 1.11) 1.01 (0.95, 1.08) Cost, insurance, and scheduling adequate 1.00 (0.93, 1.07) 1.02 (0.95, 1.10) 1.03 (0.95, 1.12) FOBT Knowledge 1.00 (0.92, 1.10) 1.03 (0.94, 1.13) 1.04 (0.94, 1.14) Feels fear, discomfort or bothered 0.95 (0.90, 1.01) 0.95 (0.90, 1.01) 0.97 (0.91, 1.03) Cost, insurance, and scheduling adequate 1.05 (0.97, 1.13) 1.00 (0.93, 1.08) 0.99 (0.91, 1.07) Doctor recommended any CRC screening test 0.9 (0.78, 1.04) 0.88 (0.75, 1.04) 0.89 (0.75, 1.06) Average risk 0.29 (0.18, 0.47) 0.18 (0.11, 0.28) 0.17 (0.11, 0.27) COL = Colonoscopy; CRC = colorectal cancer; DCBE = double-contrast barium enema; FOBT = fecal occult blood test; SIG = flexible sigmoidoscopy. Figures in bold indicate variables that are statistically significant. Odds ratio for CRC screening for these variables reflects a 1-point change along a 5-point scale.

6 A Risk-adjusted Survey 249 criteria. It also appears to be the first survey to compare CRC screening rates in patients at average and increased risk, and to assess potential barriers and facilitators, controlling for the risk for CRC. Our first objective, to characterize self-reported CRC screening behaviors under several criteria, required us to develop a tailored methodology. In the past, there has been a profusion of recommendations for CRC screening, which are typically based on underlying CRC risk, but vary in the recommended screening modalities and frequency of testing. The approach consisted of assessing adequate screening behavior by first creating a set (or sets) of screening behaviors and then assigning criteria evaluations as to whether or not each of the screening behaviors in the set met our standards as an adequate screening behavior. Complicating the identification of barriers responsible for low screening rates is the variety of screening behavior recommendations offered by the cancer research and public health communities at the time this survey was conducted, and the competing evidence justifying alternative recommendations. 25 For example, recommendations 2 endorsed by several medical organizations suggested that an annual FOBT is adequate screening behavior for people at average risk while the ACG had proposed a more aggressive approach. 20,21 Given the controversy as to what qualifies as an adequate screening behavior, the methodology we adopted permitted an examination of how different classifications of screening behaviors empirically relate to one another and how changes in the criteria of adequate screening affect classification of subjects. Furthermore, this methodology provided us a mechanism to assess the robustness of claims regarding barriers to, and facilitators of, CRC screening, by assessing the impact of those factors in a variety of adequate screening behaviors. Ultimately, the methodology permits researchers with different notions of what constitutes adequate screening to incorporate these multiple perspectives. Recently published recommendations for individuals at average risk include a broad range of options, similar to Criterion I The latest guidelines for individuals at increased risk for CRC are more varied; the USPSTF suggests screening at an earlier age while the American Gastroenterological Association (AGA) recommends a more individualized approach dependent on specific familial risk factors. 27,28 It is difficult to determine whether the proportion of subjects classified as being at increased risk in this study (36.5%) is excessive. The prevalence of polyps alone may be as high as 60 percent in industrialized nations. 29 This suggests that while a large proportion of subjects were found to be at increased risk, the proportion may not be unusual. However, the possibility also exists that the proportion at increased risk was unusually high because of selection bias those at increased risk were more likely to have participated in the survey. The self-reported screening rates we found for subjects at average risk are similar to those recently reported by the CDC. 4 In particular, 1999 data from the CDC s Behavioral Risk Factor Surveillance System found that 44.0 percent of respondents aged 50 or older (n = 63,555) had received a home-administered FOBT in the past year and/or an SIG or a COL in the past 5 years compared with 41 percent in The proportion of those respondents who were at increased risk is unknown. Nevertheless, we applied similar criteria to respondents in our survey and came up with a screening rate of 48.7 percent for patients at average risk (77.8% for those at increased risk). There are some reasons why one would expect the higher rate we observed. Our survey occurred 1 year later, dealt with respondents 51 years or older, and allowed for slightly more relaxed time constraints (1.5 years for the FOBT and 5.5 years for the SIG and COL). We also allowed for a DCBE. Nevertheless, the reader should be aware that selection bias may have produced a sample whose characteristics are not readily generalizable to the overall public s (ie, agreater proportion of respondents at increased risk). This may not have been as much of an issue for the CDC survey. Importantly, our sample was representative of the general population with respect to age, gender, and ethnicity. (US population: 55% female; 81% white; 55% years, 35% years, 11% 80+ years). Also, self-reports of screening practices may be subject to error due to recall bias, social desirability (preference to appear to conform), and low motivation for determining the exact month and date of screening. However, a recent study in an HMO population found that patient self-report for colorectal cancer screening was reliable, with sensitivity ranging from 89 to 96 percent and the specificity varying from 86 to 97 percent, depending on which test was used. 30 Reassuringly, screening rates for those at increased risk were higher than those for people at average risk. Since many persons defined as being at increased risk became so defined as a result of an abnormal initial screening test (ie, at a time when they were at average risk), this is not surprising. Nevertheless, substantial room for improvement exists for both groups. According to Criterion I, which is similar to the most recent recommendations, more than 51 percent of the respondents at average risk reported that they have not engaged in any adequate screening behavior. Furthermore, the screening strategy generally recommended for individuals at increased risk (a COL every 5 years) at the time the survey was conducted, was not followed by a large percentage of those individuals, as 43.7 percent reported not having a colonoscopy within the past 5 1 / 2 years. On the basis of this study s findings, it is

7 250 Journal of Public Health Management and Practice suggested that educational programs may be a useful approach to enhancing screening in this group. The significance of gender in this study that men appear more likely to conform to screening criteria than women appears to be counter to the conventional wisdom with respect to health-promotion activities. This may be due to a strong self-selection effect, where only men interested in cancer screening participated in the survey. However, our findings are consistent with a large, national survey that found men were more likely to undergo CRC screening than women. 5 Furthermore, the equal distribution of gender across risk groups suggests that the differences between average risk and increased risk responses is not due to gender bias in the sample. Hence, the gender differences we found may be real, rather than the result of a self-selection problem. Almost 2,000 of the some 2,400 individuals contacted refused to participate in the survey. Given the number of questions and the length of the survey ( 30 min), it was a challenge to recruit willing participants. The study confirms that personal and family history of CRC or related symptoms, and receipt of information/advice related to them, are strongly associated with higher levels of CRC screening. The study reinforces and updates findings of studies done on smaller cohorts restricted by geography, age, or ethnicity as well as a similar national-level study conducted nearly 20 years ago on a comparably sized population ,31 Previous studies have concluded that information campaigns addressed to such groups as minority ethnic groups, women, and the elderly would be associated with higher screening rates ,31 Our study broadens this message to the general population. That is, our findings suggest that the screening rates and conformance with screening criteria of men as well as women, younger as well as older subjects, Whites as well as African Americans, Asian Americans, and Hispanics all seem to be higher when they have received information/advice related to cancer screening. We identified relatively few barriers and facilitators, a finding previously reported in studies of other populations Interestingly, we did not find fear and discomfort of screening tests to be a barrier to CRC screening. In a survey of patients and physicians attitudes toward CRC screening tests, 15 percent of patients stated that discomfort was the most important feature in selecting a CRC screening test, in contrast to 64 percent of physicians perceptions of patients values. This suggests that clinicians may not be able to correctly perceive which factors are important to patients. 31 Finally, the negative association between smoking and adequate screening, in conjunction with the positive association between personal health concern and screening, reinforces the differences between key target populations. Effective alternative strategies should be available both for those who are more concerned about health and those who are less concerned. Colorectal cancer remains one of the few neoplasms for which screening has been shown to lead to significant decreases in morbidity and mortality. In addition, several diagnostic screening modalities are available, and recommended screening strategies have been formulated that permit a range of clinical environments. Yet screening rates remain low. Through its focus on lay attitudes toward colorectal cancer screening, this study identifies opportunities to engage patients so they can be properly screened against a leading malignancy that is largely preventable REFERENCES 1. National Cancer Institute. SEER cancer statistics review, Available at: Publications/CSR Accessed April 4, Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112(2): American Gastroenterological Association. Clinical Symposium: Genetic Testing for Colon Cancer Susceptibility. Program and abstracts of Digestive Week 2001; May 20 23; Atlanta, Georgia. 4. Centers for Disease Control and Prevention. Trends in screening for colorectal cancer United States, 1997 and MMWR Morbid Mortal Wkly Rep. 2001;50: Breen N, Wagener DK, Brown ML, Davis WW, Ballard- Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst. 2001;93: Schroy PC 3 rd, Geller AC, Crosier Wood M, et al. Utilization of colorectal cancer screening tests: a 1997 survey of Massachusetts internists. Prev Med. November 2001;33: Zack DL, DiBaise JK, Quigley EM, Roy HK. Colorectal cancer screening compliance by medicine residents: perceived and actual. Am J Gastroenterol. October 2001;96: Hawley ST, Levin B, Vernon SW. Colorectal cancer screening by primary care physicians in two medical care organizations. Cancer Detect Prev. 2001;25: Puschel K, Thompson B, Coronado GD, Lopez LC, Kimball AM. Factors related to cancer screening in Hispanics: a comparison of the perception of Hispanic community members, health care providers, and representatives of organizations that serve Hispanics. Health Educ Behav. October 2001;28: Lee MM, Lee F, Stewart S, McPhee S. Cancer screening practices among primary care physicians serving Chinese Americans in San Francisco. West J Med. March 1999;170: Cooper GS, Fortinsky RH, Hapke R, Landefeld CS. Factors associated with the use of flexible sigmoidoscopy as a screening test for the detection of colorectal carcinoma by primary care physicians. Cancer. 15 April 1998;82: Holmes-Rovner M, Williams GA, Hoppough S, Quillan L, Butler R, Given CW. Colorectal cancer screening barriers in

8 A Risk-adjusted Survey 251 persons with low income. Cancer Pract. September October 2002;10: James AS, Campbell MK, Hudson MA. Perceived barriers and benefits to colon cancer screening among African Americans in North Carolina: how does perception relate to screening behavior? Cancer Epidemiol Biomarkers Prev. June 2002;11: Weitzman ER, Zapka J, Estabrook B, Goins KV. Risk and reluctance: understanding impediments to colorectal cancer screening. Prev Med. June 2001;32: Tang TS, Solomon LJ, McCracken LM. Barriers to fecal occult blood testing and sigmoidoscopy among older Chinese- American women. Cancer Prev. November Drecember 2001;9: Wolf RL, Zybert P, Brouse CH, et al. Knowledge, beliefs, and barriers relevant to colorectal cancer screening in an urban population: a pilot study. Fam Community Health. October 2001;24: Mandelson MT, Curry SJ, Anderson LA, et al. Colorectal cancer screening participation by older women. Am J Prev Med. October 2000;19: Dominitz JA, Provenzale D. Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol. December 1997;92: Shapiro JA, Seeff LC, Nadel MR. Colorectal cancer-screening tests and associated health behaviors. Am J Prev Med. 2001;21(2): Rex DK, Johnson DA, Lieberman DA, et al. Colorectal Cancer Prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol. 2000;95(4): Bond JH, for the Practice Parameters Committee of the American College of Gastroenterology. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Am J Gastroenterol. 2000;95(11): Weller DP, Owen N, Hiller JE, Wilson K, Wilson D. Colorectal cancer and its prevention: prevalence of beliefs, attitudes, intentions and behavior. Aust J Public Health. 1995;19(1): Rawl SM, Menon U, Champion VL, Foster JL, Skinner CS. Colorectal cancer screening beliefs: focus groups with first degree relatives. Cancer Pract. 2000;8(1): Blalock SJ, DeVellis BM, Afifi RA, Sandler RS. Risk perceptions and participation in colorectal cancer screening. Health Psychol. 1999;9: Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Costeffectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284(15): Walsh JME, Terdiman JP. Colorectal cancer screening. JAMA. 2003;289(10): US Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137: Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale update based on new evidence. Gastroenterology. 2003;124: Rickett RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel. An autopsy survey. Cancer. 1979;43: Baier M, Calogne N, Cutter G, et al. Validity of selfreported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev. 2000;9(2): Macrae FA, Hill DJ, St. John DJ, Ambikapathy A, Garner JF. Predicting colon cancer screening behavior from health beliefs. Prev Med. January 1984;13: Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitutes toward colorectal cancer screening tests. J Gen Intern Med. 2002;16:

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace

More information

Screening & Surveillance Guidelines

Screening & Surveillance Guidelines Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following

More information

Colorectal Cancer Screening What are my options?

Colorectal Cancer Screening What are my options? 069-Colorectal cancer (Rosen) 1/23/04 12:59 PM Page 69 What are my options? Wayne Rosen, MD, FRCSC As presented at the 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) There are

More information

CENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female.

CENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female. A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC) 5 Key Messages Screening reduces mortality from CRC All persons aged 50 years and older should begin regular screening High-risk

More information

Colon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership

Colon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk

More information

Colorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018

Colorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018 Colorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018 Issue Summary The American Cancer Society has updated its colorectal screening guideline, which have been published in CA: A Journal

More information

Colorectal Cancer Screening. Paul Berg MD

Colorectal Cancer Screening. Paul Berg MD Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order

More information

Psycho-social Determinants of Colorectal Cancer Screening in Iran

Psycho-social Determinants of Colorectal Cancer Screening in Iran www.ijpm.in www.ijpm.ir Psycho-social Determinants of Colorectal Cancer Screening in Iran Hamideh Salimzadeh, Hassan Eftekhar 1, Alireza Delavari, Reza Malekzadeh Digestive Oncology Research Center, Digestive

More information

Early detection and screening for colorectal neoplasia

Early detection and screening for colorectal neoplasia Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.

More information

Financial Disclosers

Financial Disclosers Slide 1 Colorectal Cancer Screening Jason Hemming, MD NESGNA November 15, 2014 Slide 2 Bio Slide 3 Financial Disclosers I have no actual or potential conflict of interest relation to this presentation

More information

Increasing the number of older persons in the United

Increasing the number of older persons in the United Current Capacity for Endoscopic Colorectal Cancer Screening in the United States: Data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices Martin L. Brown, PhD, Carrie N.

More information

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Increasing Colorectal Cancer Screening in Wyoming Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Overview What is colorectal cancer? What are risk factors for

More information

Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.

Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D. Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,

More information

Screening Patients with a Family History of Colorectal Cancer

Screening Patients with a Family History of Colorectal Cancer Screening Patients with a Family History of Colorectal Cancer Robert H. Fletcher, MD, MSc 1,4, Rebecca Lobb, MPH 1, Mark R. Bauer, MD 2, James Alan Kemp, MD, MPH 2, Richard C. Palmer, DrPH 3, Ken P. Kleinman,

More information

2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)

2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests) Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,

More information

Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Efficiency DESCRIPTION:

More information

Comparison of Self-reported Fecal Occult Blood Testing with Automated Laboratory Records among Older Women in a Health Maintenance Organization

Comparison of Self-reported Fecal Occult Blood Testing with Automated Laboratory Records among Older Women in a Health Maintenance Organization American Journal of Epidemiology Copyright 01999 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol.150,. 6 Printed In USA. Comparison of Self-reported Fecal Occult

More information

Cancer Screenings and Early Diagnostics

Cancer Screenings and Early Diagnostics Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6

More information

Colorectal Cancer Screening

Colorectal Cancer Screening Colorectal Cancer Screening Colorectal cancer is preventable. Routine screening can reduce deaths through the early diagnosis and removal of pre-cancerous polyps. Screening saves lives, but only if people

More information

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an

More information

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers Colorectal Cancer Screening in Ohio CHCs Ohio Association of Community Health Centers 2 1/29/2015 Your Speakers Dr. Ted Wymyslo Ashley Ballard Randy Runyon 3 1/29/2015 Facts 3 rd most common cancer in

More information

Increasing Breast Cancer Screening: Multicomponent Interventions

Increasing Breast Cancer Screening: Multicomponent Interventions Increasing Breast Cancer Screening: Multicomponent Interventions Community Preventive Services Task Force Finding and Rationale Statement Ratified August 2016 Table of Contents Intervention Definition...

More information

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy

More information

Overcoming Barriers to Cancer Screening. Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer American Cancer Society

Overcoming Barriers to Cancer Screening. Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer American Cancer Society Overcoming Barriers to Cancer Screening Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer American Cancer Society Cancer Disparities Cancer Disparities: A Definition Cancer health disparities

More information

Research. Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour

Research. Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour Ryan Zarychanski MD, Yue Chen PhD, Charles N. Bernstein MD, Paul C. Hébert MD MHSc @ See related article

More information

Cologuard Screening for Colorectal Cancer

Cologuard Screening for Colorectal Cancer Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for

More information

Colorectal cancer screening: Is total prevention possible?

Colorectal cancer screening: Is total prevention possible? Just the facts colorectal cancer Colorectal cancer screening: Is total prevention possible? Jeffrey Fox, MD, MPH Concepts and Controversies 2011 2010 NCI estimates for US: 142, 570 new CRC diagnoses 51,370

More information

article MATERIALS AND METHODS

article MATERIALS AND METHODS September 2006 Vol. 8 No. 9 article Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention Scott D. Ramsey, MD, PhD 1,2, Paula Yoon, ScD,

More information

Colorectal Cancer Screening: A Clinical Update

Colorectal Cancer Screening: A Clinical Update 11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,

More information

ASSESSMENT OF PHYSICIANS COLORECTAL CANCER SCREENING PRIORITIES USING THE ANALYTIC HIERARCHY PROCESS (AHP)

ASSESSMENT OF PHYSICIANS COLORECTAL CANCER SCREENING PRIORITIES USING THE ANALYTIC HIERARCHY PROCESS (AHP) ASSESSMENT OF PHYSICIANS COLORECTAL CANCER SCREENING PRIORITIES USING THE ANALYTIC HIERARCHY PROCESS (AHP) James G. Dolan, MD * Department of Community and Preventive Medicine University of Rochester Rochester,

More information

Colorectal Cancer Screening in Later Life: Blum Center Rounds

Colorectal Cancer Screening in Later Life: Blum Center Rounds Colorectal Cancer Screening in Later Life: Blum Center Rounds OCTOBER 10, 2018 Agenda CRC Screening and Surveillance Recommendation Screening for Colon Cancer later in life Discussion and listening Families

More information

Knowledge, Perceptions, and Communication about Colorectal Cancer Screening among Chinese American Primary Care Physicians

Knowledge, Perceptions, and Communication about Colorectal Cancer Screening among Chinese American Primary Care Physicians SHORT REPORT Knowledge, Perceptions, and Communication about Colorectal Cancer Screening among Chinese American Primary Care Physicians Wenchi Liang 1, Mei-Yuh Chen 1, Grace X. Ma 2 and Jeanne S. Mandelblatt

More information

Addressing Colorectal Cancer Disparities in Arkansas

Addressing Colorectal Cancer Disparities in Arkansas Addressing Colorectal Cancer Disparities in Arkansas Collaborating Institutions Winthrop P. Rockefeller Cancer Institute Fay W. Boozman College of Public Health Arkansas Department of Public Health Arkansas

More information

Special Cancer Behavioral Risk Factor Survey, 2008

Special Cancer Behavioral Risk Factor Survey, 2008 Special Cancer Behavioral Risk Factor Survey, 28 April 21 Table of Contents Introduction... 1 Methodology... 1 The Survey Instrument... 1 Interview Protocols... 2 Response Rates... 2 The Sample... 3 Analysis...

More information

Page 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.

Page 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A. Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts

More information

Page 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!

Page 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice! Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!

More information

Thank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements

Thank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements Thank You to Our Sponsors: University at Albany School of Public Health NYS Department of Health Evaluations & CE Credits Nursing Contact Hours, CME and CHES credits are available. Please visit www.phlive.org

More information

Colorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital

Colorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital Colorectal Cancer Screening Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital March, 2018 CRC Epidemiology 4th most common malignancy in US (136,000 cases/yr) 2nd

More information

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC) Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer

More information

ORIGINAL INVESTIGATION. Disparities in Colon Cancer Screening in the Medicare Population

ORIGINAL INVESTIGATION. Disparities in Colon Cancer Screening in the Medicare Population ORIGINAL INVESTIGATION Disparities in Colon Cancer Screening in the Medicare Population Ashwin N. Ananthakrishnan, MD, MPH; Kenneth G. Schellhase, MD, MPH; Rodney A. Sparapani, MS; Purushottam W. Laud,

More information

Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer

Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer Healthy Habits and Cancer Screening Rev 10.20.15 Page

More information

Colorectal Cancer Screening

Colorectal Cancer Screening Tool 2.1 Cancer Screening Basic Fact Sheet Are You at High Risk? Your risk for colorectal cancer may be higher than average if: stomach You or a close relative have had colorectal polyps or colorectal

More information

Preventive Care and Screening

Preventive Care and Screening Clinical Performance Measures Preventive Care and Screening Tools Developed by Physicians for Physicians Provided by: Physician Consortium for Performance Improvement Purpose This measurement tool provides

More information

What Questions Should You Ask?

What Questions Should You Ask? ? Your Doctor Has Ordered a Colonoscopy. What Questions Should You sk? From the merican College of Gastroenterology www.acg.gi.org Normal colon Is the doctor performing your colonoscopy a Gastroenterologist?

More information

VERSION STUDENT. Cases in Population-Oriented Prevention (C-POP)-based teaching cases. A Critical Look at Prevention: Colorectal Cancer Screening

VERSION STUDENT. Cases in Population-Oriented Prevention (C-POP)-based teaching cases. A Critical Look at Prevention: Colorectal Cancer Screening STUDENT VERSION This project has the objective to develop preventive medicine teaching cases that will motivate medical students, residents and faculty to improve clinical preventive competencies complemented

More information

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,

More information

Increasing Colorectal Cancer Screening Rates Why it s not as easy as you ve been told

Increasing Colorectal Cancer Screening Rates Why it s not as easy as you ve been told INCREASING COLORECTAL CANCER SCREENING IN NYS Increasing Colorectal Cancer Screening Rates Why it s not as easy as you ve been told 5/15/17 Syracuse, NY Martin C. Mahoney, MD, PhD Roswell Park Cancer Institute

More information

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society

More information

Colorectal Cancer Screening and Risk Assessment Workflow. Documentation Guide for Health Center NextGen Users

Colorectal Cancer Screening and Risk Assessment Workflow. Documentation Guide for Health Center NextGen Users Colorectal Cancer Screening and Risk Assessment Workflow Documentation Guide for Health Center NextGen Users Colorectal Cancer Screening and Risk Assessment Workflow and Documentation Guide for Health

More information

ACS Colorectal Cancer Screening Guideline for Average Risk Adults 2018

ACS Colorectal Cancer Screening Guideline for Average Risk Adults 2018 ACS Colorectal Cancer Screening Guideline for Average Risk Adults 2018 1 How are Cancer Screening Guidelines Developed? ACS Guideline Development Process Systematic Evidence Review & Modeling Reports [existing

More information

Balancing Fidelity and Adaptation

Balancing Fidelity and Adaptation Balancing Fidelity and Adaptation If We Want More Evidence-Based Practice, We Need more Practice-Based Evidence Lawrence W. Green University of California at San Francisco TIDIRH, Tuesday Morning Definitions

More information

Knowledge of Colorectal Cancer Screening Guidelines and Intention to Obtain Screening Among Nonadherent Filipino, Hmong, and Korean Americans

Knowledge of Colorectal Cancer Screening Guidelines and Intention to Obtain Screening Among Nonadherent Filipino, Hmong, and Korean Americans Original Article Knowledge of Colorectal Cancer Screening Guidelines and Intention to Obtain Screening Among Nonadherent Filipino, Hmong, and Korean Americans Janice Y. Tsoh, PhD 1,2 ; Elisa K. Tong, MD

More information

BACKGROUND. Screening is effective in reducing the incidence and mortality of

BACKGROUND. Screening is effective in reducing the incidence and mortality of 2093 Patterns and Predictors of Colorectal Cancer Test Use in the Adult U.S. Population Laura C. Seeff, M.D. 1 Marion R. Nadel, Ph.D., M.P.H. 1 Carrie N. Klabunde, Ph.D. 2 Trevor Thompson, B.S. 1 Jean

More information

2017 CANCER ANNUAL REPORT

2017 CANCER ANNUAL REPORT 2017 CANCER ANNUAL REPORT A WORD FROM OUR LEADERSHIP We are pleased to present our 2017 Annual Report highlighting advances in state of the art cancer care at the Roper St. Francis Cancer Program. Our

More information

African Americans: To screen earlier? Chyke Doubeni, MD, FRCS, MPH

African Americans: To screen earlier? Chyke Doubeni, MD, FRCS, MPH African Americans: To screen earlier? Chyke Doubeni, MD, FRCS, MPH Department of Family Medicine and Community Health Perelman School of Medicine Senior Scholar, Center for Clinical Epidemiology and Biostatistics

More information

ACG Clinical Guideline: Colorectal Cancer Screening

ACG Clinical Guideline: Colorectal Cancer Screening ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,

More information

Colorectal cancer screening

Colorectal cancer screening 26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant

More information

EBI 1 Description: Automated Telephone Calls to Improve Completion of Fecal Occult Blood Testing

EBI 1 Description: Automated Telephone Calls to Improve Completion of Fecal Occult Blood Testing EBI 1 Description: Automated Telephone Calls to Improve Completion of Fecal Occult Blood Testing Description Automated Telephone Calls Improve Completion of Fecal Occult Blood Testing is an automated telephone

More information

1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757)

1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757) 1101 First Colonial Road, Suite 300, Virginia Beach, VA 23454 www.vbgastro.com Phone (757) 481-4817 Fax (757) 481-7138 1150 Glen Mitchell Drive, Suite 208 Virginia Beach, VA 23456 www.vbgastro.com Phone

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,

More information

Improving Compliance with Fecal Occult Blood Tests, a Colorectal Cancer Screening Tool

Improving Compliance with Fecal Occult Blood Tests, a Colorectal Cancer Screening Tool Improving Compliance with Fecal Occult Blood Tests, a Colorectal Cancer Screening Tool Joseph Krakowiak Matthew Walker Comprehensive Health Center Nashville, TN Introduction National avg rate of CRC screening

More information

Colorectal Cancer in Idaho November 2, 2006 Chris Johnson, CDRI

Colorectal Cancer in Idaho November 2, 2006 Chris Johnson, CDRI Colorectal Cancer in Idaho 2002-2004 November 2, 2006 Chris Johnson, CDRI cjohnson@teamiha.org Colorectal Cancer in Idaho, 2002-2004 Fast facts: Colorectal cancer is the second leading cause of cancer

More information

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD, MACG 1, C. Richard Boland, MD 2, Jason A. Dominitz,

More information

Updates In Cancer Screening: Navigating a Changing Landscape

Updates In Cancer Screening: Navigating a Changing Landscape Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA

More information

HOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING. Using your toolkit to conduct an evaluation

HOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING. Using your toolkit to conduct an evaluation EVALUATION TOOLKIT HOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING Using your toolkit to conduct an evaluation Welcome Mary Doroshenk, MA Director National

More information

Page 1. Controversies in Cancer Prevention and Screening. Disclosures. Screening. Principles of Screening. I have no conflicts of interest

Page 1. Controversies in Cancer Prevention and Screening. Disclosures. Screening. Principles of Screening. I have no conflicts of interest Controversies in Cancer Prevention and Screening Disclosures Using the Best Evidence in 2015 I have no conflicts of interest Judith M.E. Walsh, MD, MPH Division of General Internal Medicine Women s Health

More information

Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview

Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview Cancer Types Rev. 10.20.15 Page 35 Colorectal Cancer Overview Group Discussion True False Not

More information

COLON CANCER SCREENING: AN UPDATE

COLON CANCER SCREENING: AN UPDATE Overview COLON CANCER SCREENING: AN UPDATE Siddharth Verma, DO, JD Rutgers New Jersey Medical School Background Screening Updates in Specific Populations African Americans CRC in the younger age USPSTF

More information

Colon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011

Colon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011 Colon Cancer Screening and Surveillance Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011 Colorectal Cancer Preventable cancer Number 2 cancer killer in the USA Often curable if detected

More information

Results from the 2001 California Health Interview Survey. BACKGROUND. Recent research has supported the use of colorectal cancer (CRC)

Results from the 2001 California Health Interview Survey. BACKGROUND. Recent research has supported the use of colorectal cancer (CRC) 2523 A Population-Based Study of Colorectal Cancer Test Use Results from the 2001 California Health Interview Survey David A. Etzioni, M.D., M.S.H.S. 1,2 Ninez A. Ponce, Ph.D., M.P.P. 3 Susan H. Babey,

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: January 15, 2018 Related Policies: None Virtual Colonoscopy/Computed Tomography Colonography Description Computed tomography colonography (CTC), also known as

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Analysis of Human DNA in Stool Samples as a Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Analysis of Human DNA in Stool Samples as a Technique for

More information

A: PARTICIPANT INFORMATION

A: PARTICIPANT INFORMATION A: PARTICIPANT INFMATION 1. What is your age today? Years of age 2. What is the date of your birth? Month: Day: Most of the questions we will be asking you in this follow-up questionnaire are about the

More information

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening. Summary

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening. Summary Page: 1 of 11 Last Review Status/Date: March 2015 Technique for Colorectal Cancer Screening Summary Detection of genetic abnormalities associated with colorectal cancer in stool samples has been proposed

More information

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer Clinical Policy: to Screen for Colorectal Cancer Reference Number: CP.MP.125 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding

More information

RESEARCH ARTICLE. Breast Cancer Screening Disparity among Korean American Immigrant Women in Midwest

RESEARCH ARTICLE. Breast Cancer Screening Disparity among Korean American Immigrant Women in Midwest DOI:10.22034/APJCP.2017.18.10.2663 RESEARCH ARTICLE among Korean American Immigrant Women in Midwest Hee Yun Lee 1 *, Mi Hwa Lee 2, Yoo Jeong Jang 3, Do Kyung Lee 4 Abstract Purpose: Using three breast

More information

California Colon Cancer Control Program (CCCCP)

California Colon Cancer Control Program (CCCCP) California Colon Cancer Control Program (CCCCP) Diane Keys, CCCCP Program Director Chronic Disease Control Branch MISSION OF THE CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Dedicated to optimizing the health

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior

More information

Cancer Prevention and Control, Client-Oriented Screening Interventions: Reducing Client Out-of-Pocket Costs Colorectal Cancer (2008 Archived Review)

Cancer Prevention and Control, Client-Oriented Screening Interventions: Reducing Client Out-of-Pocket Costs Colorectal Cancer (2008 Archived Review) Cancer Prevention and Control, Client-Oriented Screening Interventions: Reducing Client Out-of-Pocket Costs Colorectal Cancer (2008 Archived Review) Table of Contents Review Summary... 2 Intervention Definition...

More information

Increasing Colorectal Cancer Screening in a Safety-net Health System with a Focus on the Uninsured: Benefits and Costs

Increasing Colorectal Cancer Screening in a Safety-net Health System with a Focus on the Uninsured: Benefits and Costs Increasing Colorectal Cancer Screening in a Safety-net Health System with a Focus on the Uninsured: Benefits and Costs Samir Gupta, MD Assistant Professor Department of Internal Medicine Division of Digestive

More information

How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE

How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov 11 2017 R. Sáenz, FACG,FASGE Wheel has been discovered already Policy Planning Thanks to GBD Big Data CRC

More information

In its October 5, 2015, draft recommendation (draft

In its October 5, 2015, draft recommendation (draft USPSTF Colorectal Cancer Screening Guidelines: An Extended Look at Multi-Year Interval Testing Barry M. Berger, MD, FCAP; Marcus A. Parton, SB; and Bernard Levin, MD, FACP Managed Care & Healthcare Communications,

More information

Examining the Influence of Cost Concern and Awareness of Low-cost Health Care on Cancer Screening among the Medically Underserved

Examining the Influence of Cost Concern and Awareness of Low-cost Health Care on Cancer Screening among the Medically Underserved Examining the Influence of Cost Concern and Awareness of Low-cost Health Care on Cancer Screening among the Medically Underserved Alicia L. Best, Alcha Strane, Omari Christie, Shalanda Bynum, Jaqueline

More information

FECAL OCCULT BLOOD TEST

FECAL OCCULT BLOOD TEST MEDICAL POLICY For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS FECAL OCCULT BLOOD TEST Policy Number: CMP - 023 Effective Date: January 1, 2018 Table

More information

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics

More information

Prevalence and Correlates of Skin Cancer Screening among Middle-aged and Older White Adults in the United States

Prevalence and Correlates of Skin Cancer Screening among Middle-aged and Older White Adults in the United States CLINICAL RESEARCH STUDY Prevalence and Correlates of Skin Cancer Screening among Middle-aged and Older White Adults in the United States Elliot J. Coups, PhD, a Alan C. Geller, MPH, RN, b Martin A. Weinstock,

More information

A senior s guide for preventative healthcare services Ynolde F. Smith D.O.

A senior s guide for preventative healthcare services Ynolde F. Smith D.O. A senior s guide for preventative healthcare services Ynolde F. Smith D.O. What can we do to prevent disease? Exercise Eating Well Keep a healthy weight Injury prevention Mental Health Social issues (care

More information

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries for Medicare Beneficiaries Policy: Based on our review of the available evidence, the IEHP UM Subcommittee adopts the use of Cologuard TM - a multi-target stool DNA test as a colorectal cancer screening

More information

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,

More information

Cancer screening is an important example of secondary

Cancer screening is an important example of secondary Med/Psych Update COLORECTAL CANCER SCREENING High-value intervention: Providing colorectal cancer screening Mortality from colorectal cancer is elevated among the mentally ill; watchfulness helps level

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions

More information

Colorectal Cancer Screening. Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL Ph:

Colorectal Cancer Screening. Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL Ph: Colorectal Cancer Screening Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL 32308 Ph: 850-297-0351 What we ll be talking about How common is colorectal cancer? What is colorectal cancer?

More information

Stool DNA-based versus colonoscopy-based colorectal cancer screening: Patient perceptions and preferences

Stool DNA-based versus colonoscopy-based colorectal cancer screening: Patient perceptions and preferences Family Medicine and Community Health Stool DNA-based versus colonoscopy-based colorectal cancer screening: Patient perceptions and preferences Matthew V. Abola 1, Todd F. Fennimore 1, Marcia M. Chen 1,

More information

Re: U.S. Preventive Services Task Force (USPSTF) Draft Recommendation Statement: Aspirin to Prevent Cardiovascular Disease and Cancer

Re: U.S. Preventive Services Task Force (USPSTF) Draft Recommendation Statement: Aspirin to Prevent Cardiovascular Disease and Cancer October 12, 2015 Albert L. Siu, MD, MSPH Chairperson U.S. Preventive Services Task Force 540 Gaither Road Rockville, MD 20850 Re: U.S. Preventive Services Task Force (USPSTF) Draft Recommendation Statement:

More information

Sources of Black-White Differences in Cancer Screening and Mortality

Sources of Black-White Differences in Cancer Screening and Mortality Sources of Black-White Differences in Cancer Screening and Mortality Abstract In 1971, President Nixon initiated the war on cancer, which led to dramatic increases in spending on cancer research and treatment.

More information

Behavioral Risk Factors in Adults

Behavioral Risk Factors in Adults Behavioral Risk Factors in Adults Behavioral risk factors are behaviors that increase the possibility of disease, such as smoking, alcohol use, bad eating habits, and not getting enough exercise. Because

More information

Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U

Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Record Status This is a critical abstract of an economic evaluation

More information

Screening for Colorectal Cancer in the Elderly. The Broad Perspective

Screening for Colorectal Cancer in the Elderly. The Broad Perspective Screening for Colorectal Cancer in the Elderly Charles J. Kahi, MD, MSCR Indiana University School of Medicine Richard L. Roudebush VA Medical Center Indianapolis, Indiana ACG Regional Midwest Course Symposium

More information